UPDATE: BMO Capital Markets Reiterates on Teva Pharmaceutical Industries Ltd. Following Announcement of CEO Resignation
October 31, 2013 at 11:21 AM EDT
In a report published Thursday, BMO Capital Markets analyst David Maris reiterated an Outperform rating on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA ), but lowered the price target from $49.00 to $44.00. In the report, BMO Capital Markets noted, “In surprising news today, Teva announced the resignation of its president
